Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review.

"Declarations Conflict of interestMD, DCG, AS, and EJL are employees of, and/or stock/shareholders in, GSK. MS is a contracted employee of GSK and does not hold stocks or shares in GSK. CR and LL are employees of PPD Evidera, which received funding from GSK to conduct the study. Ethical approvalOnly publicly available papers were included in this SLR, and no human subjects were involved; ethics approval was therefore not required. Informed consentNot applicable. Consent to participateNot applicable. Consent to publishNot applicable. Conflict of interest MD, DCG, AS, and EJL are employees of, and/or stock/shareholders in, GSK. MS is a contracted employee of GSK and does not hold stocks or shares in GSK. CR and LL are employees of PPD Evidera, which received funding from GSK to conduct the study."

"Funding This study was funded by GSK in collaboration with Vir Biotechnology, Inc. (study number 219682)."

"This SLR included observational studies investigating clinical outcomes and viral load in patients treated with sotrovimab published in peer-reviewed journal articles, preprint articles, and conference abstracts between January 1, 2022 and November 3, 2022. Although we originally sought to investigate both clinical and viral outcomes, we subsequently decided to focus on clinical outcomes in this paper as these are most useful for those considering the use of sotrovimab in clinical practice. The SLR was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (PROSPERO registration number: CRD42022376733) []. The decision to focus on clinical outcomes and omitting viral load distinguishes this SLR from the original PROSPERO protocol."